Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Valneva said data from the Phase Ib portion of an open-label, dose-escalation, Austrian and Hungarian Phase I trial in 81 healthy volunteers >65 years of age showed that 4 vaccinations with 75 and 200...